- Home
- KZR vs SACH Comparison
KZR vs SACH Comparison
Compare KZR & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | SACH |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 46.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZR | SACH |
|---|---|---|
| Price | $7.36 | $1.03 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.00 | $2.00 |
| AVG Volume (30 Days) | 88.4K | ★ 176.1K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 19.61% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $145.00 |
| Revenue Next Year | N/A | $6.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.80 |
| 52 Week High | $7.55 | $1.35 |
Technical Indicators
Market Signals| Indicator | KZR | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 57.42 |
| Support Level | $6.06 | $1.05 |
| Resistance Level | N/A | $1.12 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 89.12 | 78.57 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.